The Monoclonal Antibody (MAb) Facility (MAF) provides non-commercially-available antibodies to MD Anderson Cancer Center investigators for specific applications. The MAF serves basic, translational and clinical researchers across the institution and is currently developing projects in each of these three areas. Although the services are based on """"""""traditional"""""""" murine hybridoma technology, the MAF offers custom immunization strategies and support for functional screening in order to produce unique antibodies suitable for novel applications. The MAF occupies 726 sq. ft. in 1SCRB, home to the Center for Cancer Immunology Research (CCIR) on the South Campus. This is a state-of-the-art facility for immunology research that provides a platform for integrating basic and clinical research programs. The CCIR is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tank rooms, and glassware washing and sterilization facilities, all of which are available to the MAF. The MAF has a tissue culture laboratory (SCR 4.2158), a protein chemistry area (SCR 4.2220), and space in the South Campus Vivarium that is a component of the Research Animal Support Facility shared resource. In the last 5-year period, the MAF developed three MAbs that have potential for clinical development as therapeutic agents, and several additional candidates are in preclinical assessment. Several antibodies produced by the MAF have been licensed or are in the process of being licensed for commercial development. MD Anderson members with peer-reviewed funding accounted for 97% of the usage of the resource and 30% support is requested from the CCSG. Since 2007, the MAF has supported the research of 40 MD Anderson investigators with peer reviewed funding representing 16 CCSG Programs, compared to 13 investigators in the previous grant period. Hybridoma production increased from 44 to 79 projects (a 178% increase), and total services provided increased more than 300% during this grant cycle. Publications cited using the MAF have appeared in Nature, PNAS, Blood and Nature Medicine. Future plans include the purchase of a bioreactor for large scale production to support the increasing demand for the quantities of MAbs required for preclinical development Novel methods of immunization including DNA expression will be explored. The facility also plans to explore the direct generation of """"""""fully human antibodies"""""""" using """"""""humanized"""""""" mice or using Phage display scFv libraries as a more rapid and direct strategy to produce antibodies for future clinical applications of newly-discovered markers.

Public Health Relevance

The MAF develops high-quality, cost-effective customized MAbs to meet the basic, translational, and clinical research needs of MD Anderson investigators. Rates are comparable to other institutions across the country and, in some cases, significantly lower. Many of the MAbs generated have been licensed or patented.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Yedururi, Sireesha; Terpenning, Silanath; Gupta, Sanjay et al. (2017) Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence. J Comput Assist Tomogr 41:607-613
Montalban-Bravo, G; Huang, X; Jabbour, E et al. (2017) A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31:318-324
Tadros, Audree B; Smith, Benjamin D; Shen, Yu et al. (2017) Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg :
Ikoma, Naruhiko; Raghav, Kanwal; Chang, George (2017) An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am 26:667-687
Alhuraiji, Ahmad; Jain, Nitin (2017) Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 10:33-34
Lin, Heather Y; Bedrosian, Isabelle; Babiera, Gildy V et al. (2017) Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123:2618-2625
Rozovski, Uri; Harris, David M; Li, Ping et al. (2017) Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15:610-618
Masarova, Lucia; Kantarjian, Hagop; Garcia-Mannero, Guillermo et al. (2017) Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95
Palacios, Cristina; Daniel, Carrie R; Tirado-Gómez, Maribel et al. (2017) Dietary Patterns in Puerto Rican and Mexican-American Breast Cancer Survivors: A Pilot Study. J Immigr Minor Health 19:341-348
Gunther, Jillian R; Chadha, Awalpreet S; Shin, Ui Sup et al. (2017) Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol 2:455-464

Showing the most recent 10 out of 10289 publications